Status:
COMPLETED
Age and Refraction in Predicting Myopia Progression in COVID-19
Lead Sponsor:
Tianjin Eye Hospital
Conditions:
Refraction Error
Myopia
Eligibility:
All Genders
6-15 years
Brief Summary
To determine the longitudinal changes of age and refraction in predicting myopia progression with risk under the coronavirus disease 2019 (COVID-19) pandemic in a 3-year follow-up of a Chinese cohort.
Detailed Description
This was part of the large-scale Tianjin Eye Study, a population-based cohort study that longitudinally investigates the relationship between the age, refraction, and development of childhood RE in Ti...
Eligibility Criteria
Inclusion
- no concurrent eye disease;
- age 6-15 years.
Exclusion
- significant systemic illnesses
- ocular conditions that could affect the corneal curvature, including congenital corneal diseases,
- pterygium, keratoconus, other corneal degeneration or dystrophy conditions,
- media opacity, uveitis, glaucoma
- a history of intraocular surgery, refractive surgery,
- neurologic or retinal diseases, current corneal refractive therapy (ortho-K),
- low-dose atropine therapy for myopia control
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
34400 Patients enrolled
Trial Details
Trial ID
NCT05305274
Start Date
October 1 2019
End Date
December 1 2021
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Eye Hospital
Tianjin, China, 300020